Both parties publicly confirmed the AstraZeneca collaboration. A 2026 financing announcement states that proceeds will advance the pipeline into clinical development; specific human oral PK data were not disclosed.
Mainland ChinaFull profile →
Company database
Profiles, sources, and comparisons are open. Choose a field on the left to see its companies.
Search & refine Filters update automatically
Disease tags identify mentions in recorded facts or pipeline text, not approved indications or a complete pipeline. Platform service providers may have no disease-specific tag.
11 matching companiesShowing 1–11 / 11
The company website confirms the Macoral® / Simgut® platform and collaboration with BrightGene. The pipeline image reviewed is historical; current clinical stages require confirmation.
Mainland ChinaFull profile →
Iterative design, synthesis, and experimental optimization improve synthetic macrocyclic peptide potency, selectivity, and permeability. The company collaborates with argenx on oral macrocycle programs.
United StatesFull profile →
Uses AI, physics-based simulation, peptide chemistry, and oral formulation development for oral immunology and cardiometabolic peptides; operates in Shanghai and Pennsylvania.
Mainland China / United StatesFull profile →
nGen combines AI and automated synthesis to optimize oral properties of nCycles and has a multi-target cardiometabolic collaboration with Novo. The company describes nCycles as fully synthetic macrocyclic NCEs.
Denmark / SwitzerlandFull profile →
The PDPS-derived oral peptide pipeline includes a myostatin program listed as IND-enabling, plus other oral candidates; it is recorded separately from the radiopharmaceutical peptide pipeline.
JapanFull profile →
The company disclosed a patent for an oral semaglutide nanoparticle formulation. This is a noncyclic peptide delivery reference, not clinical validation for cyclic peptides.
South KoreaFull profile →
The website separately describes H1K, an oral anti-obesity candidate, and ESAIDD cyclic peptide discovery. This review could not confirm that H1K is cyclic or has human results.
South KoreaFull profile →
Works with Orbis on oral macrocycle discovery and with Vivtex on delivery. Success with oral semaglutide does not automatically validate the collaborative macrocycle program.
DenmarkFull profile →
LIPFENDRA is a U.S.-approved oral PCSK9 inhibitor. Its label confirms sodium caprate and approximately 1% oral bioavailability.
United StatesFull profile →
RNA medicines developer. On October 27, 2026, Wave reported WVE-007 in Phase 2a and WVE-006 in Phase 1b/2a; its registrational trial remained planned.
United StatesFull profile →
Coverage expands from sourced records; this database does not claim all biopharma companies.